Dr. Reddy's Laboratories Ltd. (RDY)

36.61
NYSE : Health Technology
Prev Close 36.60
Day Low/High 36.06 / 37.00
52 Wk Low/High 28.13 / 39.96
Avg Volume 276.00K
Exchange NYSE
Shares Outstanding 165.99M
Market Cap 5.96B
EPS 0.90
P/E Ratio 40.22
Div & Yield 0.27 (0.81%)

Latest News

Dr. Reddy's Q2 & H1 FY19 Financial Results

Dr. Reddy's Q2 & H1 FY19 Financial Results

Dr. Reddy's Laboratories Ltd.

Dr. Reddy's Laboratories Receives Approval For Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Receives Approval For Aspirin And Extended-Release Dipyridamole Capsules In The U.S. Market

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr.

Dr. Reddy's To Release Q2 FY19 Results On October 26, 2018

Dr. Reddy's To Release Q2 FY19 Results On October 26, 2018

Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) will announce results for the quarter ended September 30, 2018 on Friday, October 26, 2018 after the Board Meeting.

Dr. Reddy's Q1 FY19 Financial Results

Dr. Reddy's Q1 FY19 Financial Results

Dr. Reddy's Laboratories Ltd.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Dr. Reddy's Laboratories Limited (RDY)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of Dr. Reddy's Laboratories Limited (RDY)

NEW YORK, July 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dr.

Indivior Soars on Court Ruling Blocking Sales of Rival's Generic Opioid Drug

Indivior Soars on Court Ruling Blocking Sales of Rival's Generic Opioid Drug

The drug company received a preliminary injunction blocking Dr. Reddy's Laboratories from selling its opioid treatment drug.

Dr. Reddy's To Release Q1 FY19 Results On July 26, 2018

Dr. Reddy's To Release Q1 FY19 Results On July 26, 2018

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the quarter ended June 30, 2018 on Thursday, July 26, 2018 after the Board Meeting.

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy's Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2018 was filed with the United States...

Dr. Reddy's Laboratories Limited To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Dr. Reddy's Laboratories Limited To Present At The Goldman Sachs 39th Annual Global Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Goldman Sachs 39 th Annual Global Healthcare Conference on Wednesday, June 13 th, 2018, in California.

Dr. Reddy's Laboratories Limited To Present At The Jefferies 2018 Healthcare Conference

Dr. Reddy's Laboratories Limited To Present At The Jefferies 2018 Healthcare Conference

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Jefferies 2018 Healthcare Conference on Wednesday, June 6 th, 2018, in New York City.

Dr. Reddy's To Release Q4 And Full Year FY18 Results On May 22, 2018

Dr. Reddy's To Release Q4 And Full Year FY18 Results On May 22, 2018

Dr. Reddy's Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Fourth Quarter and Full year ended March 31, 2018 on Tuesday, May 22, 2018 after the Board Meeting.

Dr. Reddy's Laboratories And Its U.S. Subsidiary Promius Pharma Announce The Filing Of An NDA For Its Migraine Candidate

Dr. Reddy's Laboratories And Its U.S. Subsidiary Promius Pharma Announce The Filing Of An NDA For Its Migraine Candidate

Dr. Reddy's Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and its subsidiary, Promius Pharma, LLC today announced the filing of New Drug Application (NDA) for its migraine candidate DFN-02 with the U.

Dr. Reddy's Laboratories Announces Senior Leadership Changes

Dr. Reddy's Laboratories Announces Senior Leadership Changes

Dr. Reddy's Laboratories Ltd.

TheStreet Quant Rating: C (Hold)